Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;55(6):105988.
doi: 10.1016/j.ijantimicag.2020.105988. Epub 2020 Apr 17.

Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?

Sun Hee Lee  1 , Hyunjin Son  2 , Kyong Ran Peck  3
Affiliations

Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?

Sun Hee Lee et al. Int J Antimicrob Agents. 2020 Jun.

Abstract

In the context of the ongoing global outbreak of coronavirus disease 2019 (COVID-19), management of exposure events is a concern. Long-term care hospitals (LTCHs) are particularly vulnerable to cluster outbreaks because facilities for patient isolation and healthcare personnel to care for these patients in isolation are difficult to arrange in a large outbreak situation. Although several drugs have been proposed as treatment options, there are no data on the effectiveness and safety of post-exposure prophylaxis (PEP) for COVID-19. After a large COVID-19 exposure event in an LTCH in Korea, PEP using hydroxychloroquine (HCQ) was administered to 211 individuals, including 189 patients and 22 careworkers, whose baseline polymerase chain reaction (PCR) tests for COVID-19 were negative. PEP was completed in 184 (97.4%) patients and 21 (95.5%) careworkers without serious adverse events. At the end of 14 days of quarantine, all follow-up PCR tests were negative. Based on our experience, further clinical studies are recommended for COVID-19 PEP.

Keywords: COVID-19; Hydroxychloroquine; Long-term care hospital; Post-exposure prophylaxis; SARS-CoV-2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Timeline of exposure period, quarantine and post-exposure prophylaxis. Ⓐ Pink line indicates the route of patient A (the index case) while symptomatic, Ⓑ Red line indicates the route of patient B (the second case) while symptomatic, ① Patient A, attended a religious service in Daegu, ② Patient A, symptom onset, ③ Patient A, diagnosed with COVID-19, ④ Hospital closed and contacts quarantined, COVID-19 tests for all patients and hospital staff, ⑤ Patient B, diagnosed with COVID-19, ICU patients transferred to the other hospital, ⑥ Patients and careworkers, initiated post-exposure prophylaxis with hydroxychloroquine, ⑦ Patients and hospital staff, follow-up COVID-19 tests, ⑧ Discontinuation of isolation, quarantine and post-exposure prophylaxis with hydroxychloroquine. F, floor; GW, general ward; ICU, intensive care unit; OC, outpatient clinic; PT, physical therapy room; XR, X-ray room
See this image and copyright information in PMC

References

    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733. - PMC - PubMed
    1. Korean Society of Infectious Diseases KSoPID, Korean Society of Epidemiology, Korean Society for Antimicrobial Therapy, Korean Society for Healthcare-associated Infection Control and Prevention, and Korea Centers for Disease Control and Prevention Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020;35:e112. - PMC - PubMed
    1. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006;6:67–69. - PMC - PubMed
    1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. - PMC - PubMed
    1. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquinone for the treatment of severe acute respiratory syndrome coronarvirus 2 (SARS-CoV-2) Clin Infect Dis. 2020 Mar 9 doi: 10.1093/cid/ciaa237. ciaa237. - DOI - PMC - PubMed

Substances